Formation of charge-polarized regions at dual single-atom sites for C-H bond activation in methane.
Direct conversion of CH into liquid oxygenates under mild conditions is of great significance but remains challenging due to the high dissociation energy of inert C-H bond.
APA
Chen D, Zhou J, et al. (2026). Formation of charge-polarized regions at dual single-atom sites for C-H bond activation in methane.. Nature communications, 17(1). https://doi.org/10.1038/s41467-026-69822-1
MLA
Chen D, et al.. "Formation of charge-polarized regions at dual single-atom sites for C-H bond activation in methane.." Nature communications, vol. 17, no. 1, 2026.
PMID
41723155
Abstract
Direct conversion of CH into liquid oxygenates under mild conditions is of great significance but remains challenging due to the high dissociation energy of inert C-H bond. Here we report the fabrication of a dual atomic Fe and Pd catalyst with periodic macroporous structure (Fe-Pd OMNC) toward the direct CH conversion at room temperature. Mechanism studies reveal that a charge polarization region (O-Fe-Pd) is formed in-situ on Fe-Pd atomic sites upon oxidant activation, wherein the electron-rich O and electron-deficient Pd regions can respectively capture the H and CH in CH and lead to the activation of C-H bond. As a result, Fe-Pd OMNC demonstrates attractive photothermal catalytic performance toward the selective oxidation of CH under Xe lamp irradiation, achieving the productivities of C1 oxygenates as high as 0.754 mmol h and 0.035 mmol h when using HO or O as the oxidant, respectively.
같은 제1저자의 인용 많은 논문 (5)
- Discovery of as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer.
- Enhanced Immunotherapy for Glioblastoma Using a Cholesterol Oxidase-Loaded, Pd-Doped CuN Nanozyme-Based Multimodal Nanoplatform.
- Clinicopathological and Genomic Analysis of -Deficient Non-Small Cell Lung Cancer: A Retrospective Cohort Study.
- Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional Microtumors.
- IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.